Rocket Pharmaceuticals Receives Funding from the California Institute for Regenerative Medicine (CIRM)
Rocket Pharmaceuticals, Inc. (RCKT)
Last rocket pharmaceuticals, inc. earnings: 3/5 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
rocketpharma.com
Company Research
Source: Business Wire
- $6.5mm Grant to Fund U.S. Phase I/II Leukocyte Adhesion Deficiency-I Registration-Enabling Study - NEW YORK--(BUSINESS WIRE)-- Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) (“Rocket”), a leading U.S.-based multi-platform clinical-stage gene therapy company, today announces that the California Institute for Regenerative Medicine (CIRM) has awarded Rocket a $6.5mm CLIN2 grant award to support the clinical development of gene therapy for Leukocyte Adhesion Deficiency-I (LAD-I). The CIRM was founded in 2004 following the passing of Proposition 71 or the California Stem Cell Research and Cures Initiative, which allocated $3 billion in state funding for stem cell research conducted in California. Rocket’s Investigational New Drug Application (IND) for RP-L201 was accepted by the U.S. Food and Drug Administration in November 2018. Proceeds from the grant will help fund clinical trial costs as well
Show less
Read more
Impact Snapshot
Event Time:
RCKT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RCKT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RCKT alerts
High impacting Rocket Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
RCKT
News
- Why Is Rocket Pharmaceuticals (RCKT) Down 13.6% Since Last Earnings Report? [Yahoo! Finance]Yahoo! Finance
- Rocket Pharmaceuticals Announces Appointment of Aaron Ondrey as Chief Financial Officer and Additional Updates to Corporate Leadership Team [Yahoo! Finance]Yahoo! Finance
- Rocket Pharmaceuticals Announces Appointment of Aaron Ondrey as Chief Financial Officer and Additional Updates to Corporate Leadership TeamBusiness Wire
- Rocket Pharmaceuticals' Promising Path In Gene Therapy [Seeking Alpha]Seeking Alpha
- Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) had its price target lowered by analysts at UBS Group AG from $56.00 to $54.00. They now have a "buy" rating on the stock.MarketBeat
RCKT
Earnings
- 2/26/24 - Beat
RCKT
Sec Filings
- 3/25/24 - Form 4
- 3/25/24 - Form 4
- 3/21/24 - Form 144
- RCKT's page on the SEC website